DENVER, Colo., Jun 11, 2024 (247marketnews.com)- Molecular Partners AG (NASDAQ:MOLN) debuted its lead Radio-DARPin therapy (RDT) candidate MP0712, targeting DLL3, in an oral presentation that included data supporting MP0712’s clinical development in small-cell lung cancer (SCLC) and other DLL3 neuroendocrine tumors.
“Three years ago, we started our venture into the radiotherapy space. We have made tremendous progress with our Radio-DARPins and are proud to present MP0712, our first RDT development candidate targeting DLL3 delivering and Pb to kill the tumor, in partnership with Orano Med,” commented Molecular Partners’ Chief Executive Officer, Patrick Amstutz, Ph.D. “We have made key learnings how to reduce kidney accumulation and increase tumor uptake. We are now exploiting the long-known DARPin advantages to a full pipeline of candidates addressing high medical need. Kudos to both the Orano Med and Molecular Partners team for advancing the science to make this happen.”
Julien Dodet, CEO of Orano Med, stated, “We are extremely excited with the first preclinical results of the MP0712 program, which confirm the potential of the combination between Molecular Partners’ targeting technology and Pb, an isotope perfectly suited for targeted alpha therapy. We eagerly anticipate advancing the drug’s development and initiating clinical trials to provide solutions for patients with unmet medical needs.”
The post Molecular Partners and Orano Med Share Positive DLL3 Preclinical Data appeared first on 24/7 MarketNews.